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Background
Disease modifying treatment options for patients with
HAM are limited. Most studies have included all patients
regardless of duration, disability or disease activity. The
Medical Research Council UK funded a series of proof of
concept studies for patients with early (50% deterioration
during preceding 3 months). The results of the first study
of ciclosporin have been published. The second study,
of the anti-TNF monoclonal antibody Infliximab, is
presented.
Study design
Open-label, clinical endpoint study of Infliximab 3mg/kg
infused intravenously at weeks 0, 2 and 8 and then
every 8 weeks until and including week 40 of the study.
Primary endpoints were time to and incidence of clinical
failure.
Results
The study was terminated early for futility. Three patients
were recruited to and completed the study. Patient #1
developed a rash and headache after the 2nd infusion.
This was considered to be immune complex mediated.
Patient #2 experienced hypersensitivity reaction with pro-
found hypotension during the 4th infusion (week 16). In
both cases treatment was discontinued. Patient #3 com-
pleted all 7 infusions without adverse effect. Reduced
spasticity was observed in all 3 patients during on-
treatment period. Patient #1 was unable to stand
throughout the study. 10m timed walk improved in
Patient #2 but deteriorated in #3. No trend was observed
in pain scores, b2M or HTLV-1 viral load in blood
and CSF.
Conclusion
High severe adverse event rate with Infliximab therapy was
observed. Future studies should co-administer with meth-
otrexate as per the treatment of rheumatoid arthritis.
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